Introduction
In the last decade, a number of studies have pointed to the existence of cells within the bone marrow (BM) endowed with muscle regenerative potential [1] [2] [3] [4] [5] [6] . Initial studies by Ferrari et al. [1] demonstrated that BM cells were capable of migrating from circulation and participate in the regeneration process of damaged muscle fibers in cardiotoxin-injured immunodeficient mice. This finding was followed by a number of reports documenting engraftment after BM transplantation into dystrophic mice [2] [3] [4] 7] . Although these results were encouraging, overall the levels of engraftment were low with less than 1% of total muscle fibers being donor-derived [2, 7] , and thus unlikely to provide functional benefit. Since the studies described above have involved the transplantation of both whole BM [7] , which contains a heterogeneous cell population, or highly purified hematopoietic stem cells (BM SP cells) [2] , one could hypothesize that such low engraftment was due to the use of a cell population with limited muscle potential.
Mesenchymal stem cells (MSCs), which reside within the stromal compartment of adult BM, have been identified as a non-hematopoietic stem cell population capable of selfrenewal and multi-lineage differentiation into mesenchymal lineages, including bone, fat, cartilage, and connective tissue [8] [9] [10] . Although less than 0.01% of the BM mononuclear cell fraction comprises MSCs [10] , their easy isolation, rapid expansion and multi-lineage differentiation draw attention to their therapeutic potential in regenerative medicine and tissue
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engineering. Unlike other mesenchymal lineages (such as adipocytes or osteoblasts), skeletal myoblasts have not been easily differentiated from MSCs. Initial induction protocols to differentiate MSCs into myogenic progenitors have employed 5-azacytidine [11] , a strong demethylating agent associated with muscle gene activation, in particular MyoD [12] [13] [14] . The drawback of this non-physiological method is excessive cell death, which results in virtually none [15] or very few surviving cells that are then endowed with myogenic features (not shown). A more reasonable approach consists of culturing MSCs with myoblasts [16] or myoblast-conditioned medium [15] . Recently, galectin-1 has been identified as a soluble factor present in myoblast-conditioned medium, that has the capacity to promote myogenic conversion of dermal fibroblasts [17] and fetal MSCs [15] . This conversion seems to occur via activation of the myogenic regulatory factors (MRFs), including Myf-5, MyoD, and myogenin [15] , as observed during embryonic myogenesis [18] [19] [20] . Another reported approach [21] made use of activated Notch to generate skeletal muscle cells from human MSCs. Although the results were somewhat encouraging, the rationale for using Notch1 was not made clear.
During embryogenesis, all skeletal muscles, except for those of the head are derived from transient condensations of paraxial mesoderm, the somites, located next to the neural tube and notochord [22] . Signals from these structures lead to patterning of the somite to form the sclerotome, a precursor for the skeleton, and the dermomyotome, the precursor for both dermis and muscle [22, 23] . Cells expressing the transcription factor Pax3 within the dermomyotome migrate medially through the dorsomedial lip of the dermomyotome to form an epithelial sheet, known as the myotome [24] . At this site myogenesis occurs [25, 26] upon activation of MRFs, including Myf-5, Mrf4, MyoD, and myogenin. Since the role of Pax3 upstream of MRFs is essential for embryonic muscle specification [18, 19, 24, [27] [28] [29] [30] , we investigated the potential of Pax3 to drive myogenesis from a murine MSC as well as its effects on other mesenchymal lineages.
Materials and methods

Cell lines and culture conditions
MSCB9, a murine mesenchymal stem cell line generated in our laboratory as previously described [31] was used for the experiments. These cells were maintained in MSC expansion medium consisting of low-glucose Dulbecco's modified Eagle's medium (LG-DMEM; Invitrogen) supplemented with 40% Molecular Cell Developmental Biology (MCDB)-201 medium (Sigma), 10% fetal bovine serum (FBS, Invitrogen), 1× insulin-transferrin-selenium (ITS; Sigma), 1× linoleic-acid-bovine serum-albumin (Sigma), 10 M ascorbic acid 2-phosphate (Sigma), 50 U/ml penicillin/streptomycin (Invitrogen) and the following growth factors: 10 ng/ml of recombinant human platelet-derived growth factor-BB (hPDGF-BB; R&D Systems), 10 ng/ml of recombinant murine epidermal growth factor (mEGF; Sigma), and 1000 U/ml of recombinant murine leukemia inhibitory factor (LIF, Chemicon). BEND3, a mouse endothelial cell line (generously provided by Dr. R. Brekken, UT Southwestern Medical Center), and NIH 3T3 fibroblasts were maintained in LG-DMEM supplemented with 10% FBS, 2 mM Lglutamine (Invitrogen) and antibiotics. Medium was changed twice a week. For sub-culture, cells were trypsinized with 0.25% Trypsin-EDTA (Invitrogen) and replated at a subcultivation ratio of 1:3. C2C12 cells [32] cells were suspended in 5 ml of viral supernatant containing 10 ng/ml hPDGF-BB, 10 ng/ml mEGF, 1000 U/ml mLIF and 8 μg/ ml hexadimethrin bromide (polybrene; Sigma). Cells were then transferred to 6-well plates and centrifuged at 2500 rpm for 90 min at 33°C on a Hettich centrifuge. After an overnight incubation at 37°C with 5% CO 2 in air, supernatant was removed and changed with fresh MSC expansion medium (10 ng/ml hPDGF-BB, 10 ng/ml mEGF, 1000 U/ml mLIF), as described above. A similar approach was used for BEND3 and NIH3T3 cells, except for the culture medium which consisted of LG-DMEM supplemented with 10% FBS. Two days following infection, cells were harvested and analyzed on a FACS Aria (Becton-Dickinson) for GFP expression. Propidium iodide (1 μg/ ml; Pharmingen) was used to exclude dead cells. For purification, infected cells were sorted based on the gating of GFP + on the fluorescein isothiocyanate (FITC) channel.
Induction of multi-lineage differentiation in vitro
For myogenic differentiation, cells were cultured for up to 3 weeks in several muscle induction conditions as follows:
LG-DMEM supplemented with 10% fetal bovine serum, MSC expansion medium containing no growth factors, LG-DMEM supplemented with a mixture of 5% horse serum (HS) and 10% fetal bovine serum, and LG-DMEM supplemented with 5% or 2% horse serum. Multinucleated myotubes were observed under phase contrast microscope (Olympus). For adipogenic differentiation, cells were plated in the presence of Minimum Essential Medium (MEM) Alpha medium containing horse serum (12.5%), fetal bovine serum (12.5%), penicillin/streptomycin (50 U/ml), 2-mercaptoethanol (10 − 4 M; Sigma), and hydrocortisone (10 For osteogenic differentiation, cells were cultured in the presence of DMEM medium with fetal bovine serum (10%), penicillin/streptomycin (50 U/ml), ascorbic acid 2-phosphate (50 μmol/l), dexamethasone (0.1 μmol/l), and β-glycerolphosphate (10 mmol/l; Sigma). Characterization was performed by Alizarin Red S staining, which detects calcium deposition. For chondrogenesis, cells were cultured as pellets at a density of 3 ×10
5 cells/ml in serum free-chemically defined medium consisting of DMEM (high-glucose), 1× insulin-transferrinselenium, 1× linoleic-acid-bovine serum-albumin, ascorbic acid 2-phosphate (50 μg/ml), dexamethasone (100 nM) and 10 ng/ml hTGF β1 (R&D Systems). Medium was changed every two days. Paraffin-embedded pellet cultures were fixed with 10% formalin, dehydrated and cut into 5 μm-thick sections. Alcian Blue staining was used to detect cartilage formation.
Reverse transcriptase polymerase chain reaction (RT-PCR) Analysis
Total RNA was isolated using Trizol (Invitrogen) as recommended by the manufacturer. First strand cDNA was produced using Superscript II reverse transcriptase (Invitrogen) with Oligo dT. 5% of first strand reaction was used for each ensuing PCR reaction. Primer sequences and PCR conditions are described in Table 1 . For real time PCR, all probe sets were acquired from Applied Biosystems.
Immunofluorescence staining of cultured cells
Briefly, cells on coverslips were fixed in 4% paraformaldehyde/ PBS and permeabilized with 0.3% Triton X-100 (Sigma) for 15 min at room temperature. Cells were then incubated overnight at 4°C with primary antibodies including Pax3 (R&D systems), MyoD (BD Biosciences), myogenin (BD Biosciences), and MHC (Developmental Studies Hybridoma Bank). A Cy3
(Jackson Immunoresearch Laboratories) secondary antibody was used. DAPI (4,6-diamidino-2-phenylindole; Fluka) was used to counter-stain nuclei. Fusion index was defined as the percentage of nuclei belonging to MHC-positive cells with three or more nuclei. Isotype control antibodies were used as negative control staining. Immunofluorescent signals were captured and analyzed using a fluorescence microscope (Olympus) and MetaVue5.0 software.
Western blot
Western blots were performed using the following antibodies: mouse anti-MyoD (BD Biosciences), mouse monoclonal antiPax3 (R&D Systems), and mouse monoclonal anti-actin (Sigma).
Results
Pax3 directs MSCB9 cells toward the myogenic lineage
To evaluate the effect of Pax3 on the differentiation of MSCs into the myogenic lineage, we transduced Pax3 into the mesenchymal stem cell line MSCB9 [31] . One week after retroviral infection, MSCB9-Pax3 cultures contained cells with elongated morphology (Fig. 1A, left panel) , which was not observed in control vector-transduced MSCB9 cells (MSCB9-Vector) (Fig. 1A , right panel). To obtain a homogeneous population of Pax3- Figs. 2A-B) . A similar effect was also observed when cells were cultured in DMEM 10% FBS (condition 1; Figs. 2 and 3A) . (Figs. 3B-D) . Consistent with the morphological observation of myotube formation, fusion index was elevated in MSCB9-Pax3 cells (Fig. 3E) . In contrast, MSCB9-Vector cells were negative for all myogenic markers under this muscle differentiation condition (Figs. 3B-D) . Taken together, these results suggest that Pax3-transduced MSCs are capable of undergoing terminal muscle differentiation in vitro.
Pax3 blocks adipogenesis, osteogenesis and chondrogenesis of MSCs
Given that MSCB9 cells or MSCB9-Vector cells easily make adipocytes when cultured at a high density (Fig. 4A. ii) , the finding of a total absence of fat formation in MSCB9-Pax3 cells under these confluent conditions (Fig. 4A.i ) led us to hypothesize that Pax3 might direct MSCs towards the skeletal muscle lineage at the expense of the adipogenic lineage. To investigate whether Pax3 is in fact blocking adipogenesis, we cultured MSCB9-Pax3 cells in adipogenic medium. As expected, the majority of MSCB9-Vector cells differentiated into lipid vacuoles-containing adipocytes which were visualized by Oil Red O staining (Fig. 4A.iv) . In contrast, no adipocytes but a few multinucleated myotubes were found in MSCB9-Pax3 cells (Fig. 4A.iii) . These results support the hypothesis that Pax3 might prevent the differentiation of MSCs into the adipogenic lineage. The emerging question is whether Pax3 is capable of blocking the other two mesenchymal lineages, specifically osteogenesis and chondrogenesis. To address this question we subjected MSCB9-Pax3 as well as MSCB9-Vector cells to osteogenic and chondrogenic induction medium for up to 4 weeks. Accordingly, MSCB9-Vector control cells differentiated robustly into osteoblasts and chondrocytes (Fig. 4A .vi and A.viii, respectively) whereas MSCB9-Pax3 cells failed to differentiate into these lineages (Fig. 4A.v and A.vii) . These findings were corroborated by gene expression analyses for multi-lineage-specific genes (Fig. 4B) . Upon appropriate induction, MSCB9-Vector cells were positive for all the examined markers for fat, bone and cartilage but not for muscle (Fig. 4B) .
On the other hand, MSCB9-Pax3 cells expressed only musclespecific genes while markers for other mesenchymal lineages were absent (Fig. 4B) . These results suggest that Pax3 drives the commitment of MSCs toward the myogenic lineage at the expense of the adipogenic, osteogenic and chondrogenic lineages.
Can Pax3 drive any cell type towards the muscle lineage?
Since our results show a potent effect of Pax3 in driving the differentiation of MSCs towards the myogenic lineage, we next inquired whether Pax3 could drive other cell types to muscle commitment. For this, we examined the effect of Pax3 Differentiation experiments were performed in triplicate. Scale bar is 100 μm (A and C).
transduction in a mouse endothelial cell line (BEND3) and in a mouse fibroblast cell line (NIH 3T3). Both cell lines were subjected to retroviral infection with MSCV-Pax3ireGFP or vector control MSCViresGFP, as previously described for MSCB9. No morphological changes were observed two days following infection with either cell line, BEND3 (Fig. 5A .i, upper panel) or NIH 3T3 (Fig. 5A .ii, upper panel), at which point cells were sorted based on GFP expression (Fig. 5A .i-ii, middle panel). Even after this purification step, there were no apparent morphological differences between Pax3-transduced and Vector-transduced cells in BEND3 or NIH 3T3 cell lines (Fig. 5A .i-ii, lower panel). Immunofluorescence staining and western blot analyses confirmed that Pax3 was indeed expressed in Pax3-transduced cells (Fig. 5B and, respectively) . We then analyzed the gene expression profile of BEND3-Pax3 and NIH 3T3-Pax3 cells growing in the absence of any muscleinducing agent using MSCB9-Pax3 cells as reference (Fig. 5C ). MyoD and Myf5 RNAs were found in MSCB9-Pax3 and NIH 3T3-Pax3 cells although at much lower levels in the latter (Fig. 5C ), and were not present in BEND3-Pax3 cells (Fig. 5C ). Myogenin and MCK, markers of terminal skeletal muscle differentiation could be detected in NIH 3T3-Pax3 cells but at insignificant levels under this condition (data not shown). At the protein level, MyoD was detectable only in MSCB9-Pax3 cells (Fig. 5D) . Thus, despite Pax3 overexpression, BEND3 cells do not seem to have acquired any potential to differentiate towards the muscle lineage while NIH 3T3 cells display limited muscle differentiation potential.
To confirm this assumption, we attempted to induce muscle differentiation of BEND3 and NIH 3T3 cells in vitro by testing several conditions as previously described (Fig. 2B) . Muscle differentiation induction of MSCB9-Pax3 and MSCB9-Vector cells were used as positive and negative control, respectively (Fig. 6A) . Consistently with our previous results, aggregated multinucleated myotubes were formed under these conditions (Fig. 6A.i) . Myogenic markers including MyoD, Myf5, myogenin, and MCK were detected in MSCB9-Pax3 but not in MSCB9-Vector cells (Fig. 6A .ii). No signal for these genes was detected in BEND3 cells, despite Pax3 overexpression ( Fig. 6B .ii) in accordance with the lack of morphological changes (Fig. 6B.i) . Since the levels of Pax3 were not as high in BEND3 cells as in MSCB9 and NIH 3T3 cells (Fig. 5D) , we submitted BEND3-Pax3 cells with a second round of infection with Pax3. Regardless of higher expression of Pax3 (Fig. 7A) , myogenic regulatory factors were still absent (Figs. 7B-C) . These results indicate that Pax3 is not able to initiate the myogenic program in endothelial cells. On the other hand, expression of MRFs could be easily detected in NIH 3T3-Pax3 cells, in particular under condition 2 ( Fig. 6C .ii). Although this induction did not result in significant morphological changes, MyoD could be detected at the protein level. This finding is not surprising since fibroblasts are the main cell type of stromal tissues, and belong to the mesenchymal compartment. Taken together, these results suggest that Pax3 promotes the muscle commitment only in specific cell types, in particular those of mesenchymal origin.
Discussion
During mouse embryogenesis, Pax3 is first expressed in the presomitic mesoderm. This expression is maintained in the somitic epithelium of the dermomyotome, and later on (10.5 d. p.c.) in the myotome [33, 34] . Pax3 is also present in the brain, dorsally throughout the neural tube and in neural crest cells. Accordingly, Splotch (Pax3-null) mice die by E14.5 due to a number of developmental defects including impaired neural tube closure, defects in neural crest-derived structures, failure of cells within the dermomyotome to delaminate, and therefore, absence of limb muscles [24, 35, 36] . This later defect is associated with a lack of migratory muscle progenitors, which prevents MyoD activation by Myf5 and Mrf4 [20, 28, 36, 37] . Because of this important role in muscle specification, Pax3 is considered a master regulator of the embryonic myogenic program [24, 27] .
Here we demonstrate that expression of Pax3 in a murine mesenchymal stem cell line enables the activation of the myogenic program in these cells. As observed during embryogenesis, Pax3 does so by activating downstream muscle-specific genes, including MyoD, Myf5 and myogenin. In the presence of muscle induction conditions, Pax3-MSC-derived myogenic progenitors undergo final maturation by differentiating into multinucleated myotubes (Figs. 3A-E) . Previous work has demonstrated improved muscle differentiation of MSCs in the presence of Notch signaling [21] . Here the effect of Pax3 on muscle differentiation seems independent of the Notch pathway, as no up-regulation of Hes1 and Hes5, downstream targets of Notch, was observed (Fig. 8) . Interestingly, activation of the myogenic program by Pax3 occurs at the expense of other mesenchymal lineages, as observed by its inhibitory effect on adipogenesis, osteogenesis, and chondrogenesis (Figs. 4A-B) . Such transcriptional modulation has been previously described for mesenchymal lineages, in particular for fat and bone. For instance, it has been demonstrated that haploinsufficency of PPARγ-2, a key transcription factor for adipogenesis, leads to osteogenesis by increased osteoblast formation [38, 39] . Conversely, with aging, commitment of murine MSCs to the adipogenic lineage is enhanced at the expense of osteogenesis [40] , a phenotype which correlates with increased levels of PPARγ-2 [40] . While PPARγ-2 is essential to drive adipogenesis from MSCs [38, 43] , Runx2 (Cbfa1) seems to be the key player for osteoblast differentiation [41] [42] [43] . Our results show that Pax3 overexpression blocks adipogenesis, osteogenesis, and chondrogenesis potentially by inhibiting PPARγ-2 and Cbfa-1. Importantly, Pax3 enables muscle commitment specifically in MSCs. Despite Pax3 overexpression, endothelial cells fail to activate the myogenic program. Although Pax3 expression in fibroblasts results in activation of MRFs, this is not accompanied by morphological changes typical of myogenic progenitors or myotubes (Fig. 6C) . Our results show that under Pax3 activation only MSCs give rise to myogenic progenitors capable of undergoing final maturation in vitro. This cell typeselective effect of Pax3 is also observed during embryogenesis, since despite being expressed in the neural tube, Pax3 does not cause myogenesis to occur at this site.
Taken together, our data reveal the potential of regulating transcriptional pathways to direct differentiation of adult stem cells.
